Lipidomics studies on macrophages - bone marrow-derived macrophages treated with 25-hydroxy-cholesterol +/- lipid-depleted media containing compactin
Introduction | Browse | DownloadMouse-over the above links for more information
Treatment details
| LM ID | Analyte | Treatment | Time(hrs) | Sample ID | Value | Units |
|---|---|---|---|---|---|---|
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 0.0 | BCD100322A002 | 8.51 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 0.5 | BCD100322A005 | 10.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 1.0 | BCD100322A009 | 8.16 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 2.0 | BCD100322A013 | 15.3 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 4.0 | BCD100322A017 | 15.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 8.0 | BCD100322A021 | 16.2 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 12.0 | BCD100322A025 | 16 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 24.0 | BCD100322A029 | 40.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 0.0 | BCD100322A001 | 7.88 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 0.5 | BCD100322A003 | 5.87 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 1.0 | BCD100322A007 | 10.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 2.0 | BCD100322A011 | 9.92 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 4.0 | BCD100322A015 | 9.87 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 8.0 | BCD100322A019 | 14.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 12.0 | BCD100322A023 | 32.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 24.0 | BCD100322A027 | 35.7 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 0.5 | BCD100322A006 | 12.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 1.0 | BCD100322A010 | 7.48 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 2.0 | BCD100322A014 | 10.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 4.0 | BCD100322A018 | 13.7 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 8.0 | BCD100322A022 | 13.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 12.0 | BCD100322A026 | 11.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 24.0 | BCD100322A030 | 23.7 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 0.5 | BCD100322A004 | 4.04 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 1.0 | BCD100322A008 | 6.39 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 2.0 | BCD100322A012 | 6.9 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 4.0 | BCD100322A016 | 13.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 8.0 | BCD100322A020 | 7.48 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 12.0 | BCD100322A024 | 17.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 24.0 | BCD100322A028 | 19.8 | pmol/sample |